证券代码：688075 证券简称：安旭生物 公告编号：2026-003 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 1、经财务部门初步测算，杭州安旭生物科技股份有限公司（以下简称"公司"） 预计 2025 年年度实现归属于母公司所有者的净利润 7,100.00 万元到 8,500.00 万元， 与上年同期（法定披露数据）相比，将减少 10,729.53 万元到 12,129.53 万元，同 比减少 55.80%到 63.08%。 2、预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润 1,300 万元到 1,560 万元，与上年同期（法定披露数据）相比，将减少 2,229.79 万 元到 2,489.79 万元，同比减少 58.84%到 65.70%。 （三）本次业绩预告为本公司初步测算，未经注册会计师年度审计。 杭州安旭生物科技股份有限公司 三、 ...

Financial Performance Forecast - The company expects a net profit of -10,300万元 for the year 2025, representing a decline of 1,015.05% compared to the previous year's profit of -6,500万元[4] - The net profit after deducting non-recurring gains and losses is projected to be -9,120万元, a decrease of 614.56% from -5,320万元 in the same period last year[4] - Basic earnings per share are expected to be -0.4790元, down from -0.3023元 in the previous year[4] Factors Affecting Performance - The decline in performance is attributed to a significant drop in titanium dioxide product prices due to weak downstream market demand, coupled with a year-on-year increase in raw material sulfuric acid prices[6] Communication and Disclosure - The company has communicated with the accounting firm regarding the preliminary financial data, and there are no discrepancies in the earnings forecast[5] - The company emphasizes that the earnings forecast is based on preliminary estimates and the actual financial data will be disclosed in the formal 2025 annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the earnings forecast[7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 证券代码：688013 证券简称：天臣医疗 公告编号：2026-005 天臣国际医疗科技股份有限公司 2025 年年度业绩预告 （二）业绩预告情况 （1）经天臣国际医疗科技股份有限公司（以下简称"公司"）财务部门初步 测算，预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露 数据）相比，将增加3,100.00万元到3,700.00万元，同比增加59.74%到71.30%。 （2）预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利 润与上年同期（法定披露数据）相比，将增加2,700.00万元到3,100.00万元，同比 增加57.77%到66.32%。 （三） 本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：5,483.14万元。归属于母公司所有者的净利润：5,189.48 万元。归属于母公司所有者的扣除非经常性损益的净利润： ...

证券代码：600078 证券简称：澄星股份 公告编号：临2026-002 江苏澄星磷化工股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●江苏澄星磷化工股份有限公司（以下简称"公司"）本期业绩预告的具体适 用情形：净利润实现扭亏为盈； （一）利润总额：-15,625.43万元。归属于母公司所有者的净利润：-19,889.64 万元。归属于母公司所有者的扣除非经常性损益的净利润：-20,762.64万元。 ●预计2025年年度实现归属于母公司所有者的净利润为650.00万元至970.00 万元，与上年同期相比，将实现扭亏为盈； ●预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 为-5,200.00万元至-2,800.00万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经公司财务部门初步测算，预计2025年年度实现归属于母公司所有者的 净利润为650.00万元至970.00万元，与上年同 ...

Financial Projections - The estimated net profit for 2025 is projected to be a loss of RMB 140 million to RMB 160 million, representing a decrease of 37.91% to 45.67% compared to the loss of RMB 257.70 million in the previous year[3]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of RMB 128 million to RMB 148 million, a reduction of 42.69% to 50.43% from the previous year's loss of RMB 258.24 million[3]. - The company anticipates a non-recurring loss of approximately RMB -12 million for 2025, primarily due to fair value changes[7]. Business Performance - The company's pesticide business revenue has shown steady growth, but overall gross margin remains low due to intensified market competition and some innovative products still ramping up production capacity[5]. - The pharmaceutical business is in collaboration with key clients, but the short duration of these partnerships has not yet positively impacted the company's performance[6]. - The subsidiary engaged in biomass waste resource processing is facing challenges due to industry cycles and market competition, leading to a contraction in project scale and expected impairment of receivables[6]. Strategic Investments - The company is investing in innovative pharmaceutical and pesticide projects, which may pressure cash flow and profits in the short term but aims to enhance long-term competitiveness[6]. - The company will conduct impairment testing on goodwill assets, expecting to recognize goodwill impairment[6].

Financial Projections - The estimated net profit for 2025 is projected to be between -200 million and -160 million CNY, compared to -140 million CNY in the same period last year[4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between -210 million and -150 million CNY, compared to -512 million CNY in the same period last year[4]. - Estimated operating revenue for 2025 is projected to be between 340 million and 380 million CNY, compared to 335.7 million CNY in the same period last year[4]. - The estimated basic earnings per share is projected to be -0.1001 CNY, compared to -0.0701 CNY in the same period last year[4]. Loss Factors - The main reasons for the loss include industry adjustments and liquidity issues, impacting net profit by approximately -200 million to -160 million CNY due to provisions for receivables and interest expenses[6]. - The fair value decline of financial assets and penalties from debt defaults is expected to impact net profit by approximately -70 million to -40 million CNY, classified as non-recurring losses[6]. Non-Recurring Gains - Gains from the disposal of long-term equity investments and recovery of bad debts are expected to positively impact net profit by approximately 60 million to 70 million CNY, classified as non-recurring gains[6]. Financial Reporting - The financial data is preliminary and will be finalized after assessment and audit, with detailed disclosures in the 2025 annual report[7]. - The company has communicated with its accounting firm regarding the earnings forecast, with no significant discrepancies noted[5]. - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the earnings forecast[7].

新希望六和股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 | 证券代码：000876 | 证券简称：新希望 公告编号：2026-11 | | --- | --- | | 债券代码：127049 | 债券简称：希望转 2 | 三、业绩变动原因说明 报告期内，公司稳步发展与提升生猪业务，加强防疫与生产管 理，出栏规模稳健提升，各项技术指标持续改善，养殖成本持续降 低，但受生猪市场行情波动影响，生猪价格下降幅度大于成本下降 幅度，致公司生猪养殖利润较同期下降。同时，公司对部分低效种 猪及低效资产进行有序淘汰和清退，亦影响公司利润下降。 与此同时，公司在饲料业务上持续扩规模、提效率、降费用， 强化内生能力，满足市场变化下客户对产品、成本、服务的新需求， 加大海外市场投入与开发力度，驱动饲料业务进入新的增长通道， 报告期内实现饲料业务利润量利同增。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 二、与会计师 ...

证券简称：国际实业 证券代码：000159 编号：2026-07 新疆国际实业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日－2025年12月31日 2、业绩预告情况：☐ 亏损 ☑ 扭亏为盈 ☐ 同向上升 ☐ 同向下降 | 项 | 目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 盈利：约 | 3,600 | 万元 | 亏损：43,878.20 | 万元 | | | | 比上年同期增长：约 | | 108.20% | | | | 扣除非经常性损 益后的净利润 | | 盈利：约 | 3,670 | 万元 | 盈利：5,389.41 | 万元 | | | | 比上年同期下降：约 | | 31.90% | | | | 基本每股收益 | | 盈利：约 | 0.0749 | 元/股 | 亏损：0.9128 | 元/股 | 二、与会计师事务所沟通情况 本 ...

Financial Projections - The estimated net profit for 2025 is projected to be between 8,890 and 13,270 million CNY, representing a decline of 50.26% to 66.68% compared to the previous year[4]. - The net profit after deducting non-recurring gains and losses is expected to be between -13,900 and -8,460 million CNY, indicating a decline of 170.04% to 215.08% year-over-year[4]. - Basic earnings per share are projected to be between 0.03 and 0.04 CNY, down from 0.09 CNY in the same period last year[4]. - The financial data in the earnings forecast has not been audited by an accounting firm, and the final figures will be confirmed in the 2025 annual report[5][8]. Performance Decline - The decline in performance is attributed to falling market prices for key products such as photovoltaic glass and float glass, leading to reduced gross margins[6]. - A lawsuit regarding compensation for talent introduction funds resulted in a loss for the company, significantly impacting net profit[7]. Accounting and Risk Management - The company plans to make impairment provisions for related assets due to the cautious principle in accounting policies[6]. - The company emphasizes the importance of investor awareness regarding potential investment risks associated with the preliminary financial estimates[8].

Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately CNY 46 million to CNY 69 million for 2025, a decrease of about CNY 203.83 million to CNY 180.83 million compared to the previous year, representing a year-on-year decline of approximately 81.59% to 72.38%[3] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be CNY 28.8 million to CNY 51.8 million, a decrease of about CNY 157.63 million to CNY 134.63 million compared to the previous year, reflecting a year-on-year decline of approximately 84.55% to 72.21%[3] - The previous year's net profit attributable to shareholders was CNY 249.83 million, and the net profit after deducting non-recurring gains and losses was CNY 186.43 million[5] Revenue Expectations - The company anticipates operating revenue of CNY 3,964.6 million to CNY 4,382 million for 2025, which represents a year-on-year increase of 3.97% to 14.92%[3] Factors Affecting Performance - The decline in performance is primarily attributed to intensified industry competition and the depreciation of fixed assets from new projects in Poland and Anhui, which are currently ramping up production capacity[6] - The company expects to recognize goodwill impairment and long-term equity investment impairment totaling approximately CNY 146 million to CNY 161 million, significantly impacting overall performance[6] Cost Management and Efficiency - The company plans to implement cost reduction in the supply chain and improve operational efficiency as part of its profit enhancement measures[6] Forecast Validity and Disclosure - The performance forecast is based on preliminary calculations by the finance department and has not been audited by registered accountants[7] - Investors are advised to note that the forecast data is preliminary and the final financial data will be disclosed in the official 2025 annual report[8] - The company has not identified any other significant uncertainties that could affect the accuracy of this performance forecast[7]